A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
Latest Information Update: 29 May 2025
At a glance
- Drugs Amivantamab (Primary) ; Carboplatin (Primary) ; Lazertinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms PALOMA-2
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 23 May 2025 Planned primary completion date changed from 31 Oct 2025 to 17 Aug 2027.
- 25 Apr 2025 Planned End Date changed from 5 Aug 2026 to 17 Aug 2027.
- 20 Mar 2025 According to Johnson and Johnson media release, Initial results from the Phase 2 PALOMA-2 study evaluating switching to SC amivantamab among patients benefitting from IV delivery in advanced EGFR-mutated NSCLC will be presented in a poster presentation at the 2025 European Lung Cancer Congress (ELCC).